Estimating xenobiotic half-lives in humans from rat data: Influence of log P

Environmental Health Perspectives

Volumn 105, Issue 11, 1997, Pages 1204-1209

  Sarver, Jeffrey G ^a   White, Donald ^a,b   Erhardt, Paul ^b   Bachmann, Kenneth ^a,b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

Half life; Log P; Scaling; Xenobiotics

Indexed keywords

DIOXIN; POLYCHLORINATED BIPHENYL; XENOBIOTIC AGENT;

ADIPOSE TISSUE; ARTICLE; BODY WEIGHT; CALCULATION; HALF LIFE TIME; HUMAN; LIPID SOLUBILITY; NONHUMAN; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; VARIANCE;

MAMMALIA;

EID: 0031469460     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.971051204     Document Type: Article

References (45)

1. Bachmann K, Pardoe D, White D. Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect 104:400-407 (1996).
2. Reitz R, Gargas M, Andersen M, Provan W, Green T. Predicting cancer risk from vinyl chloride exposure with a physiologically-based pharmacokinetic model. Toxicol Appl Pharmacol 137:253-267 (1996).
3. Hansch C, Leo A, Hoekman D. Exploring QSAR: Hydrophobic, Electronic, and Steric Constants. Washington, DC:American Chemical Society, 1995.
4. Craig P. Drug compendium. In: Comprehensive Medicinal Chemistry: The Rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds, Vol 6 (Hansch C, Sammes P, Taylor J, eds). New York:Pergamon Press, l990;237-965.
5. Environmental Science Center, Syracuse Research Corporation, http://csc.syrres.com (1996).
6. Leo A, Hansch C, Hoekman D. MacLogP Database, version 2.0. Claremont, CA:Biobyte Corp., 1996.
7. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokin Biopharm 10:201-227 (1982).
8. Travis CC, White RK, Ward RC. Interspecies extrapolation of pharmacokinetics. J Theor Biol 142:285-304(1990).
9. Fisher HL, Shah PV, Hall LL. In vivo and vitro dermal penetration of 2,4,5,2′,4′,5′ hexachlorobinphenyl in young adult rats. Environ Res 50:120-139 (1989).
10. Van der Berg M, Jongh J, Poiger H, Olson J. The toxicokinetics and metabolism of polychlorinated dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) and their relevance for toxicity. Crit Rev Toxicol 24:1-74 (1994).
11. Corley RA, Bormett GA, Ghanayem BI. Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2- butoxyacetic acid, in rats and humans. Toxicol Appl Pharmacol 129:61-79 (1994).
12. Laine K, Kivisto, KT, Neivonen PJ. Failure of oral activated charcoal to accelerate the elimination of amiodarone and chloroquine. Hum Exp Toxicol 11:491-494 (1992).
13. Gill J, Heel RC, Fitton A. Amiodarone: an overview of its pharmacological properties and review of its therapeutic use in cardiac arrhythmias. Drugs 43:69-110 (1992).
14. Teramura T, Watanabe T, Higuchi S, Hashimoto K. Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium channel blocker, in the rat, dog, and human. Xenobiotica 25: 1237-1246 (1995).
15. Chen I, Yang C. Effects of cytochrome P4502E1 modulators on the pharmacokinetics of chlorzoxazone and 6-hydroxychlorzoxazone in rats. Life Sci 58:1575-1585 (1996).
16. Bachmann K, Sarver J. Chlorzoxazone as a single sample probe of hepatic CYP2E1 activity to humans. Pharmacology 52:169-177 (1996).
17. Kharidia J, Eddington ND. Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals. Pharmaco-kinetic and pharmacodynamic modeling using computer- assisted radio telemetry. Biopharm Drug Dispos 17:93-106 (1996).
18. Ujhelyi M, Klamens K, Vadei K, O'Rangers E, Izard M, Neefe L, Zimmerman J, Chow M. Disposition of intravenous amiodarone in subjects with normal and impaired renal function. J Clin Pharmacol 36:122-130 (1996).
19. Grene-Lerouge N, Bazin-Redureau M, Debray M, Scherrmann J. Interspecies .scaling of clearance and volume of distribution for digoxin-specific fab. Toxicol Appl Pharmacol 138:84-89 (1996).
20. Thanh-Barthet CV, Urtizberea M, Sabouraud AE, Cano NJ, Schermann JM. Development of a sensitive radioimmunoassay for fab fragments: application to fab pharmacokinetics in humans. Pharm Res 10:692-696 (1993).
21. Lave T, Dupin S, Schmitt M, Kapps M, Meyers J, Morgenroth B, Chou RC, Jaeck D, Coassolo P. Interspecies scaling of tolcapone, a new inhibitor of catechol-o-merhyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 8:839-351 (1996).
22. Frantz SW, Beskitt JL, Tallant MJ, Zourelias LA, Ballantyne B. Pharmacokinetics of ethylene glycol III. Plasma disposition and metabolic fate after single increasing intravenous, peroral, or percutaneous doses in the male Sprague-Dawley rat. Xenobiotica 26:515-539 (1996).
23. Jacobson D, Hewlett TP, Webb R, Brown ST, Ordinario AT, McMartin KE. Ethylene glycol intoxication: evaluation of kinetics and crystalluria. Am J Med 84:145-152 (1988).
24. Brown C, Wong B, Fennell T. In vivo and in vitro kinetics of ethylene oxide metabolism in rats and mice. Toxicol Appl Pharmacol 136:8-19 (1996).
25. Filser JG, Denk B, Tornqvist W, Ehrenberg L. Pharmacokinetics of ethylene in man; body burden with ethylene oxide and hydroxyethylation of hemoglobin due to endogenous and environmental ethylene.Arch Toxicol 66:157-163 (1992).
26. Anonymous. Clinical Investigator's Information Brochure for IND 966. New Jersey, 1995.
27. Sarver JG. Development of a tracer technique that utilizes a physiological pharmacokinetic model to quantitatively assess the change in mass transfer rates associated with vascular growth and the application of this technique to the evaluation of a novel bioartifical organoid [Ph.D. dissertation]. The University of Toledo, Toledo, Ohio, 1994.
28. Prescott L, McAuslane J, Freestone S. The concentration-dependent disposition and kinetics of inulin. Eur J Clin Pharmacol 40:619-624 (1991).
29. Freestone S, McAuslane JA, Prescott LF. Effects of tenoxicam on renal function and the disposition of inulin and p-aminohippurate in healthy volunteers and patients with chronic renal failure. Br J Clin Pharmacol 32:495-500 (1991).
30. Borghoff SJ, Murphy JE, Medinsky MA. Development of a physiologically based pharmacokinetic model for methyl tertiary-butyl ether and terriary-butanol in male Fischer-344 rats. Fundam Appl Toxicol 30:264-275 (1996).
31. Johnson G, Nihlen A, Lof A. Toxicokinetics and acute effects of MTBE and ETBE in male volunteers. Toxicol Lett 82/83:713-718 (1995).
32. Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G. Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 136:75-78 (1996).
33. Filser JG, Schwegler U, Csanady GA, Greim H, Kreuzer PE, Kessler W. Species-specific pharmacokinetics of styrene in rat and mouse. Arch Toxicol 67:517-530 (1993).
34. Brugnone F, Perbellini L, Wang GZ, Maranelli G, Raineri E, DeRosa E, Saletti C, Soave C, Romeo L. Blood styrene concentrations in a "normal" population and in exposed workers 16 hours after the end of the work shirt. Int Arch Occup Environ Health 65:125-130 (1993).
35. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC. Metabolites, pharmacodynamics, and pharmacokinerics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 19:36-43 (1991).
36. Loaning PE, Lien EA, Lundgren S, Kvinnsland S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22:327-358 (1992).
37. Ebiing WF, Wada DR, Scanski DR. From piecewise to full physiologic pharmacokineric modeling:applied to thiopental disposition in the rat. J Pharmacokinet Biopharm 22:259-292 (1994).
38. Homer TD, Sranski DR. The effect of increasing age on thiopental disposition and anesthetic requirement. Anesthesiology 62:714-724 (1985).
39. Lave T, Dupin S, Schmitt M, Kapps M, Meyers J, Morgenroth B, Chou RC. Jaeck D, Coassolo P. Interspecies scaling of tolcapone, a new inhibitor of catechol-o-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 8:839-851 (1996).
40. Teng R, Girard D, Gootz TD, Flouds G, Liston T. Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs and monkeys. Antimicrob Agents Chemother 40:561-566 (1996).
41. Teng R, Harris SC, Nix DE, Schentag JJ, Flouds G, Liston TE. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 36:385-394 (1995).
42. Metha S, Lu D. Interspecies pharmacokinetic scaling of BSH on mice, rats, rabbits, and humans. Biopharm Drug Dispos 16:735-744 (1995).
43. Weber LWD, Greim H. The toxicity of brominated and mixed-halogenated dibenzo-p-dioxins and dibenzofurans: an overview. J Toxicol Environ Health 50:195-215 (1997).
44. Matthews HB, Andersen MW. Effect of chlorination on the distribution and excretion of polychlorinated biphenyls. Drug Metab Dispos 3:371-380 (1975).
45. Shirai JH, Kissel JC. Uncertainty in estimated halflives of PCBs in humans: impact on exposure assessment. Sci Total Environ 187:199-210 (1996).